Gene sequencing has developed rapidly, and sequencing technology has experienced nearly 40 years of development. From the first generation of sequencing technology to the second generation of sequencing technology to the third generation of sequencing technology, "precise medical research" has been listed as a national key research and development. One of the key programs of the plan. Since 2014, manufacturers of domestically produced domestic serializers with independent intellectual property rights have started to develop their own sequencing instruments.

In 2015, hotspots in the biomedical field continued: US President Barack Obama issued the "Precision Medicine Program", Tuo won the Nobel Prize in Medicine, and made breakthroughs in the development of Ebola vaccine. Among them, the "Precision Medicine Program" was listed as one of the top ten scientific events in 2015 by Nature magazine. In 2016, “Accurate Medical Research” was listed as one of the key special projects of the national key R&D program. Gene sequencing as a sophisticated weapon for precision medicine has undergone nearly 40 years of development, and sequencing of the mainstream high-throughput sequencing (NGS) has pushed the industry to a new level.

According to incomplete statistics, in recent years, domestic NGS-related enterprises have sprung up, and it is expected to reach more than 600. This report provides an overview of the development and application of the gene sequencing industry and the domestic NGS market structure. It aims to provide authoritative, sufficient and reliable strategies and decision-making basis for relevant enterprises in the NGS field.

Chapter 1 Overview of the NGS Industry

Many consulting organizations predict that the compounding growth rate of the gene sequencing industry will be around 18%, and the growth rate will exceed 20% in the next few years. High-throughput sequencing (NGS, also known as "next-generation sequencing"), as a disruptive technology, has triggered a new technological revolution in the fields of medicine, agriculture, industry, environment, energy, etc., and promoted genomic research. Scientific research and development and clinical transformation will further lay the foundation for precision medicine.

1. Industry market size

In recent years, the gene sequencing market has developed rapidly. According to an analysis released by BCCResearch (May 2016), the global market for gene sequencing related in 2015 is about 5.9 billion US dollars. It is expected to reach nearly 13.8 billion US dollars in 2020, with a compound annual growth rate of 18.7%.

Among them, NGS is the fastest growing sub-sector in the field of genomics and has become the mainstream of the sequencing market. According to different consulting company reports, the global NGS market is expected to reach 8.5 billion U.S. dollars in 2020, and the compound annual growth rate will remain at around 21%.

According to geographical division, the NGS market can be divided into North America, Europe, Asia Pacific and others. It is expected that within a few years, North America will still occupy the largest share of the global NGS sequencing market, with little difference in share, and Asia Pacific accounts for about 20% of the market.

PU Series

JIANGSU CLS TECHNOLOGY CORP.LTD , https://www.js-cls.com